Trastuzumab biosimilar (EirGenix/Sandoz)

曲妥珠单抗生物类似药（台康生技/山德士）

Report date: 2026/04/08 16:01:10

Base Information

Drug NameTrastuzumab biosimilar (EirGenix/Sandoz)
Drug Alias NameEG-12014EGI 014A1EGI-014
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsImmunomodulators
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsStomach NeoplasmsBreast Neoplasms
Global Approved IndicationsStomach NeoplasmsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2023/11/15
Country/TerritoryUnited StatesUkraineTaiwan +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesEirgenix IncSandoz
China Registration ClassN/A

Develop Information

Active CompaniesSandoz AgAspen (Guang Dong) Pharmaceutical Co LtdEirgenix Inc +[5] 
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01FD01
Related LinksN/A